Product Description
AUR-109 (formerly known as ODM-203) is an oral, spectrum selective kinase inhibitor targeting DDR1 and SIK2 along with clinically validated targets FGFRs and VEGFRs. It is currently being evaluated in FGFR mutant bladder cancer. The unique selectivity profile allows potential expansion of indications. (Sourced from: https://www.aurigene.com/pipeline/#proprietary-pipeline)
Mechanisms of Action: DDRA Inhibitor, SIK2 Inhibitor, FGFR Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Aurigene Discovery Technologies
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Ovarian Cancer|Kidney Cancer|Colorectal Cancer
Phase 1: Lymphoma
Phase 1: Healthy Volunteers|Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02264418 |
KIDES-203 | P1 |
Completed |
Other |
2019-05-01 |
12% |
2019-05-17 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
NCT03240445 |
KIPEV | P1 |
Completed |
Healthy Volunteers |
2017-10-23 |
2019-03-21 |
Treatments |
|
NCT06760702 |
TEJAS-2 | P2 |
Terminated |
Kidney Cancer|Ovarian Cancer|Colorectal Cancer |
2026-02-01 |
12% |
2026-04-23 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/25/2019 |
News Article |
Orion Group Interim Report January-March 2019 |
|
02/05/2020 |
News Article |
Orion Group Financial Statement Release for 2019 |
|
10/23/2019 |
News Article |
Orion Group Interim Report 1–9/2019 |
|
07/17/2019 |
News Article |
Orion Group Half-Year Financial Report January–June 2019 |